Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY2606368 in Extensive-Stage Small Cell Lung Cancer
2015-005069-21Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexasertib in small cell lung cancer (SCLC) (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Best overall response (BOR) by RECIST 1.1. Started Feb 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-005069-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005069-21.